An active member and past co-chair of the Australia and New Zealand Mycoses Interest Group (ANZMIG), she has been on the steering committee for the inaugural and present guidelines for antifungal drug use. She has collaborated with the European Confederation of Medical Mycology and ISHAM on guidelines for managing rare yeast infections, mucormycosis, candidiasis and COVID-associated aspergillosis. She is a member and past secretary of the board, Mycoses Study Group Education and Research Consortium and a member of its scientific committee.

Her interests are in novel diagnostics, drug resistance and epidemiology of fungal diseases. She is an investigator on several antifungal drug trials evaluating their efficacy, safety, and including use of various dosing regimens of new antifungals within existing, and novel, drug classes. She is the present editor in chief of Medical Mycology, the societal journal of ISHAM.